» Authors » Joelle Blumberg

Joelle Blumberg

Explore the profile of Joelle Blumberg including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 813
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinerie L, de Mouzon J, Blumberg J, di Nicola L, Maisonobe P, Carel J
Horm Res Paediatr . 2021 Mar; 93(9-10):529-538. PMID: 33774631
Background: Gonadotropin-releasing hormone analogues (GnRHa) administered as depot formulations are the standard of care for children with central precocious puberty (CPP). Puberty resumes after treatment discontinuation, but little is known...
2.
Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel J
Horm Res Paediatr . 2016 Sep; 86(3):188-195. PMID: 27603324
Background/aims: To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it...
3.
Caplin M, Pavel M, Cwikla J, Phan A, Raderer M, Sedlackova E, et al.
N Engl J Med . 2014 Jul; 371(3):224-33. PMID: 25014687
Background: Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. Methods: We conducted a randomized, double-blind,...
4.
Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, et al.
J Clin Oncol . 2012 Oct; 30(35):4337-43. PMID: 23109694
Purpose: To investigate the somatostatin analog lanreotide as symptomatic treatment for inoperable bowel obstruction due to peritoneal carcinomatosis. Patients And Methods: In all, 80 patients with peritoneal carcinomatosis, inoperable malignant...
5.
Gayral F, Campion J, Regimbeau J, Blumberg J, Maisonobe P, Topart P, et al.
Ann Surg . 2009 Dec; 250(6):872-7. PMID: 19953707
Objective: Continuous intravenous infusion of somatostatin improves the natural course of digestive fistulae. Lanreotide 30 mg PR is a synthetic analogue of somatostatin with pharmacological activity extending to at least...
6.
Carel J, Blumberg J, Bougeard-Julien M, Rochiccioli P, Chaussain J, Tauber M
Horm Res . 2009 Mar; 71(4):228-36. PMID: 19258715
Background/aims: The aim of the study was to evaluate the efficacy and safety of lanreotide prolonged release (PR) 30 mg (long-acting lanreotide) in girls with constitutional tall stature (CTS). Methods:...
7.
Chanson P, Borson-Chazot F, Kuhn J, Blumberg J, Maisonobe P, Delemer B
Clin Endocrinol (Oxf) . 2008 Feb; 69(2):299-305. PMID: 18248639
Background: An essential criterion for control of acromegaly is normalization of IGF-I levels. Somatostatin analogues act to suppress IGF-I and GH levels. Objective: To assess the efficacy and safety of...
8.
Moreau J, Delavault P, Blumberg J
Clin Ther . 2006 Dec; 28(10):1485-508. PMID: 17157109
Background: Early identification of the biological activity of luteinizing hormone-releasing hormone (LHRH) paved the way for the synthesis of analogues with enhanced potency and biological properties. Early testing in animal...
9.
Carel J, Blumberg J, Seymour C, Adamsbaum C, Lahlou N
Eur J Endocrinol . 2005 Dec; 154(1):119-24. PMID: 16382000
Objective: Depot GnRH agonists are commonly used in the treatment of central precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult indications, had not previously been...
10.
Teillac P, Heyns C, Kaisary A, Bouchot O, Blumberg J
Horm Res . 2004 Oct; 62(5):252-8. PMID: 15499224
Aims: The objective of the study was to assess the pharmacodynamic equivalence of LHRH analogue triptorelin 3-month and 28-day SR formulations. Methods: Patients with documented locally advanced or metastatic prostate...